17607 Gold Plaza, Omaha, NE
402-991-8468
Patient Portal
Menu

News

Low-Effort Eats

January 15, 2020

WHEN YOU’RE EXHAUSTED FROM CHEMOTHERAPY, the daily task of preparing three square meals or even just dinner may seem like an insurmountable hurdle. But maintaining a good diet is essential during treatment.

View Article

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer

January 9, 2020

On January 8, 2020, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

View Article

Real-World Outcomes of Sipuleucel-T Treatment in PROCEED, a Prospective Registry of Men With Metastatic Castration-Resistant Prostate Cancer

December 17, 2019

Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase 3 trial Immunotherapy for Prostate Adenocarcinoma Treatment, sipuleucel-T significantly reduced the risk of death among patients with mCRPC and improved median overall survival (OS) by 4.1 months versus a placebo.1 Sipuleucel-T is recommended

Download Article

ENDOCYTE ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 VISION TRIAL OF 177LU-PSMA-617 IN PROSTATE CANCER

June 8, 2018

Endocyte, Inc. (Nasdaq:ECYT) announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE, a member of Precision Cancer Research.

View Article

The Real-Life Patient Impact of Pharmacy Benefit Managers

January 10, 2018

There is growing awareness of the problems and pitfalls with Pharmacy Benefit Managers (PBMs)
in the United States health care system. Contracted by insurance carriers to negotiate on their
behalf with pharmaceutical companies, these ‘middle men’ corporations have quietly become an
unavoidable part of our nation’s health care system.

Download Article